Amicus Therapeutics, Inc. (NASDAQ:FOLD) received approval for Pombiliti + Opfolda in Japan for treating late-onset Pompe disease (LOPD) on June 25. The two-component therapy includes Pombiliti, an enzyme for muscle cells, and Opfolda, an enzyme stabilizer. Approval has also been granted in the US, EU, UK, Canada, Australia, Switzerland, and Japan.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is an American biopharmaceutical company dedicated to developing medicines for rare diseases. The company has received multiple approvals for its Pombiliti + Opfolda treatment globally.

Investors are advised to consider other AI stocks with potentially higher returns and lower risks than FOLD. For those interested in undervalued AI stocks, a free report on the best short-term AI stock is available. Check out other investment opportunities in American semiconductor and fintech stocks.

Disclosure: None. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Amicus (FOLD) Gets Japan Approval for Pombiliti + Opfolda